Invited Speakers
Dr Ken Anderson, | |
 | Ken. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at John's Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute. He serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; on the Board of Directors and Chair of the Scientific Advisory Board of the Multiple Myeloma Research Foundation; as well as on the Board of Directors and Chair of the Leadership Committee of the Multiple Myeloma Research Consortium. He is a Doris Duke Distinguished Clinical Research Scientist and has had long term RO-1, PO-1, and SPORE NIH funding. His numerous awards including the 2001 Charles C. Lund Award of the American Red Cross Blood Services, the 2003 Waldenstrom's award for research in plasma cell dyscrasias, the 2004 Johnson & Johnson Focused Giving Award for Setting New Directions in Science and Technology, the 2005 Third Annual International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award, and the 2007 Joseph A. Burchenal Award for Clinical Research from the American Association for Cancer Research. His paradigm for identifying and validating targets in the myeloma cell and its bone marrow milieu has already provided novel therapies, and offers great promise to improve patient outcome in hematologic malignancies and solid tumors as well.
|
Dr Myron S Czuczman, | |
 | Myron S Czuczman joined the staff of Roswell Park Cancer Institute in 1992, as attending physician, Department of Medicine, and was appointed Head of the Lymphoma/Myeloma Service in 1998 and became a member of the Tumor Immunology Program in 2002 where he heads a Lymphoma Translational Research Laboratory in the Department of Immunology. He also is an Associate Professor of Medicine at the University at Buffalo (UB) School of Medicine and Biomedical Sciences. Dr Czuczman's research interests focus on monoclonal antibodies, either alone or in combination with other agents in the treatment of lymphoma, evaluating novel target-specific molecules active against lymphoma in the clinic and laboratory and studying the mechanisms-of-action and resistance pathways involving monoclonal antibodies currently used in lymphoma therapy. His clinical research has contributed to approval by the U.S. Food and Drug Administration of the first monoclonal therapy rituximab for non-Hodgkin's lymphoma in 1997. Dr Czuczman is recognised as a leader in the field of the biological therapy of lymphoma and related neoplasms and has lectured both nationally and internationally on this topic.
|
Professor Anthony Goldstone, | |
 | Tony Goldstone has been a Consultant Haematologist of the UK NHS for over 30 years and since 1999 has held a personal Chair in Haematology at University College London. He trained initially with Frank Hayhoe in Cambridge and since coming to UCH has had a major interest in dose escalation in haematological malignancy and autologous and allogeneic transplant. For 20 years he has been associated with the MRC Adult Trials in AML and ALL and has worked closely with Alan Burnett in that period. Latterly, he has taken particular personal responsibility for the UK/ECOG Adult ALL Study UKALL 12/ECOG 2993. He has given Educational Sessions at ASCO and ASH. He originally established the Lymphoma Group of the EBMT which now has well over 50,000 registrations and has been responsible for randomised trials and extensive publication from that database. He chaired the EBMT Lymphoma Group for a period of 12 years.
Professor Goldstone has also been extensively concerned with politics and medical management and for eight years between 1992 and 2000 he was the Medical Director of UCLH and very closely involved in the development and now opening of the new UCLH Hospital which is the largest single new hospital development in the UK NHS. For the last six years he has widened his portfolio in relation to the strategy for other cancers and has directed the North London Cancer Network, an organisation dedicated to attempt to integrate cancer care across the 1.5 million population and the six major hospitals in the North London sector. |
Professor Jean-Luc Harousseau, | |
 | Jean-Luc Harousseau is Professor of Hematology at the University of Nantes, Head of the Department of Clinical Haematology. He is member of the Scientific Advisory Board of the French National Cancer Institute and President of the Institut du Cancer Nantes Atlantique. He was a founder member of the Intergroupe Français du Myélome and the Groupe Ouest-Est Leucémies Aigues et Maladies du Sang. Professor Harousseau is a member of the European Haematology Association, the European Group for Blood and Marrow Transplantation, the American Society of Hematology and the American Society of Clinical Oncology. He is member of the Scientific Advisory Board of Multiple Myeloma Research Foundation and of International Myeloma Foundation. His fields of interest are therapy of acute myeloid leukemia and multiple myeloma. He received the 2005 Waldenström Award for his scientific contribution in the field of Multiple Myeloma. |
Teru Hideshima, | |
 | Dr. Hideshima received M.D. degree in 1981 and Ph.D. degree in 1990 from Fukuoka University in Japan. He has engaged in surgical oncology at Department of Surgery Fukuoka University Hospital as an assistant professor, he then joined Dr. Kenneth Anderson's laboratory at Dana-Farber Cancer Institute from 1998 to study multiple myeloma cell pathogenesis and biology. He is currently working in pre-clinical study of anti-myeloma agents as a senior scientist in Jerome Lipper Multiple Myeloma Center. His research interests include signal transduction by cytokines, and molecular mechanisms of death signals triggered by novel agents.
|
Professor Ronald Levy, | |
 | Ronald Levy is a Professor of Medicine and Chief of the Division of Oncology in the Department of Medicine at Stanford University. He is also an American Cancer Society Clinical Research Professor. Dr Levy, a Harvard graduate, received his medical degree from Stanford. In 1982 he shared the first Armand Hammer Award for Cancer Research; the next year he received the Ciba-Geigy/Drew Award in Biomedical Research. In 1999 he received the American Society of Clinical Oncology Karnofsky Award and the prestigious General Motors Charles Kettering Prize. In 2000 he was awarded the Key to the Cure Award by the Cure for Lymphoma Foundation and the Medal of Honor by the American Cancer Society. Dr Levy has received international acclaim for his work using the body's own arsenal to fight cancer. He is currently conducting clinical trials of a lymphoma vaccine. His research concentrates on the study of malignant lymphoma, which are tumors of the immune system, using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Receptor molecules present on the surface of tumor cells transmit signals for regulation of cell growth; these receptors include the immunoglobulin molecule on B cell tumors, the T cell receptor on T cell tumors. Dr Levy is using these receptors as targets for new therapies for lymphoma. |
Professor Robert Negrin, | |
 | Robert S Negrin is a professor of medicine at Stanford University. He received his undergraduate degree from the University of California at Berkeley and MD from Harvard University. He trained in medicine and hematology at Stanford University and joined the faculty in 1990. His research work has focused on cellular immunology in particular developing a more fundamental understanding of complex biological reactions such as graft versus host and graft vs tumor reactions in animal models and in the clinic. He has authored over 125 original papers and 35 book chapters. He is currently the President of the American Society of Blood and Marrow Transplantation. |
Professor Swee Lay Thein, | |
 | Swee Lay Thein is Professor of Haematology and Consultant Haematologist at King's College Hospital, London. She is head of the Division of Gene and Cell Based Therapy within King's College London School of Medicine. Her postdoctoral training included general medicine and haematology at the Royal Postgraduate Medical School, Hammersmith, Royal Free Hospital, London. This was followed by a period of research at (MRC) Molecular Haematology Unit, John Radcliffe Hospital Oxford, where she held various positions - MRC Clinical Training Fellow, Wellcome Senior Fellow in Clinical Science, MRC Senior Clinical Scientist, Reader and Honorary Consultant Haematologist. Her research concentrates on the pathophysiology and management of inherited red blood cell disorders in particular, the thalassaemias and sickle cell disease. She has contributed significantly to the understanding of genetic modifiers and complex traits, and DNA diagnostics in haemoglobinopathies. Professor Thein is Editor of the Red Cell Section of BloodMed, a haematology website (joint venture between Blackwells and British Society of Haematology). She has served as Scientific Advisor to the British Society of Haematology and the National Heart, Lung, and Blood Institute of the National Institutes of Health, and is a member of the MRC College of Experts. |
Dr Richard Benjamin, | |
 | Richard Benjamin MBChB, PhD, FRCPath, Chief Medical Officer, ARC National Headquarters, joined the American Red Cross from the Joint Program in Transfusion Medicine at Harvard University, where he most recently served as Medical Director of the Adult Transfusion Service. He received Transfusion Medicine and Pathology training at the Brigham and Women's Hospital, Boston, before joining the faculty. Dr Benjamin continues to conduct clinical research in Transfusion Medicine where has work focuses on complications of transfusion and the optimization of a safe and adequate blood supply. This work builds on his research experience as a PhD student at Cambridge University, England in Immunology and post-doctoral research at Stanford University, CA. |
Dr Jürgen Bux, MD PhD, | |
 | Jürgen Bux is medical director of the Blood Service "West"of the German Red Cross and professor of transfusion medicine at the University of Bochum, Germany. He studied medicine at the University of Giessen, Germany, and did his residency at the University Hospital and at the Institute for Clinical Immunology and Transfusion Medicine in Giessen. In 1990 he was appointed as consultant in Transfusion Medicine. His PhD thesis in 1994 looked at the clinical significance of granulocyte antigens and antibodies. In 1995, he was lecturer in clinical immunology and transfusion medicine, and from 2002 to 2004 he was medical director of the Bernese Blood Transfusion Service, Switzerland. |
Dr Geoff Daniels, | |
 | Geoff Daniels is a Senior Research Fellow at the Bristol Institute for Transfusion Sciences and Head of Molecular Diagnostics at the International Blood Group Reference Laboratory of NHS Blood and Transplant, England. His research interests cover the molecular genetics of human blood groups and the expression of surface markers on erythroid cells during erythropoiesis. Dr Daniels is President Elect of the British Blood Transfusion Society and will become President in September 2007. He has received awards from the BBTS, AABB, ISBT, and the German Transfusion Society. He chairs the committee of the ISBT that provides a genetical classification and terminology for all human blood groups. Dr Daniels has published two editions of the textbook Human Blood Groups and a small reference book, Essential Guide to Blood Groups, plus numerous original scientific papers, reviews and book chapters. |
Dr Thomas J Raife, | |
 | Dr Raife's research interest is in the pathophysiology and treatment of thrombotic microangiopathy syndromes. His research explores mechanisms of microvascular thrombosis, correlations between disease factors and clinical course, and treatments for thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Dr Raife received his medical degree at the University of Iowa College of Medicine. His post-graduate training was in Pathology and Blood Banking/Transfusion Medicine. He is a former Associate Investigator at the Blood Research Institute, Milwaukee, Wisconsin, and is now Associate Professor and Section Director Transfusion Medicine at the University Of Iowa Carver College Of Medicine. |
Professor Christopher Silliman, | |
 | Christopher Colton Silliman received a BS from Haverford College (1981) and a Doctor of Medicine (1985) and Doctorate in Cell Biology (1987) from Tulane University. He completed his Pediatrics residency training at The University of Virginia (1989), and Pediatric Hematology-Oncology fellowship at The University of Colorado School (1992). He is a tenured, Professor of Pediatrics at the University of Colorado and is an Associate Medical Director at Bonfils Blood Center. His research interests include TRALI and neutrophil physiology. Dr. Silliman was married in 1992 to Lori Ann Blumberg and has three children, Harper 8, Maggie 6, and Emily 3. |
Dr Ian J Mackie, | |
 | Ian Mackie is Reader in Haemostasis and Thrombosis at University College London, where he teaches and supervises postgraduate students as well as directing the research laboratories.His interests centre on mechanisms of thrombosis, including: antiphospholipid antibodies, thrombotic thrombocytopaenic purpura, point of care testing, and the kallikrein-kinin system. He is currently President of the British Society for Haemostasis and Thrombosis, a member of the British Society for Haematology, a Fellow of the Royal College of Pathologists and the Institute of Biomedical Sciences. He graduated in 1976 and has always worked in the field of haemostasis, his early experience being in hospital laboratories. |
Dr Claude Negrier, | |
 | Claude Negrier is head of the Hematology Department at Edouard Herriot University Hospital in Lyon, France and director of the Haemophilia Comprehensive Care Centre at this institution. He is also Professor of Haematology at the Lyon School of Medicine and Adjunct Professor in the Division of Hematology at the University of North Carolina, Chapel Hill, USA. One of Dr Negrier's research interests focuses on clinical evaluation of therapeutic modalities in patients who have developed an inhibitor and clinical utility of surrogate markers. |
Dr Alan Nurden, | |
 | Alan Nurden is Research Director I, CNRS, France and scientific co-ordinator of the Reference Centre for Inherited Diseases of Platelets. His lifelong career interest has been characterising rare hereditary bleeding syndromes resulting from quantitative or qualitative abnormalities of platelet function and/or production. He has participated in the elucidation of the molecular pathways responsible for platelet adhesion and platelet aggregation, and of the mode of action of anti-thrombotic drugs that inhibit platelet receptors. His recent involvements had been the characterization of the P2Y12, ADP receptor and its pathology and is currently improving diagnosis and molecular characterisation of defects in signaling pathways of platelets. He is also looking for ways to improve patient care in a group with rare diseases and this has proved to be of value to our understanding of cardiovascular disease and its therapy. In 2002 he was awarded the Prix Danièle Hermann of the French Foundation for Cardiovascular Research of the Institut de France and in 2001 he received a "Distinguished Career Award" of the International Society on Thrombosis and Haemostasis. |
Conference Secretariat:
Festival City Conventions
PO Box 949
Kent Town SA 5071
Australia
Tel: +61 8 8363 1307
Fax: +61 8 8363 1604
haa@fcconventions.com.au
Wednesday, 10 October 2007, 09:05:04
http://www.fcconventions.com.au/HAA2007/speakers.html
pages.on.net
Festival City Conventions
PO Box 949
Kent Town SA 5071
Australia
Tel: +61 8 8363 1307
Fax: +61 8 8363 1604
haa@fcconventions.com.au
Wednesday, 10 October 2007, 09:05:04
http://www.fcconventions.com.au/HAA2007/speakers.html
pages.on.net